Mycoplasma hyopneumoniae remains a significant challenge facing U.S. swine producers. It can have economic impacts on a production system, particularly in the grow-finish phase, due to losses in average daily gain, feed efficiency and increased medication costs. The elimination of MHP can provide a positive ROI in a matter of months and provide significant health- and cost-saving advantages to downstream performance. A critical component of a successful MHP elimination program involves medication with antimicrobials. Two classes of injectable antibiotics labeled for MHP treatment and control are offered in Norbrook’s extensive anti-infective portfolio. Joining us to discuss these solutions is Dr. Megan Bollin, swine technical services for Norbrook.